BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ng SM, Moore HS. Drug therapies for reducing gastric acidity in people with cystic fibrosis. Cochrane Database Syst Rev. 2016;CD003424. [PMID: 27546383 DOI: 10.1002/14651858.cd003424.pub4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Gifford AH, Sanville JL, Sathe M, Heltshe SL, Goss CH. Use of proton pump inhibitors is associated with lower hemoglobin levels in people with cystic fibrosis. Pediatr Pulmonol 2021;56:2048-56. [PMID: 33860641 DOI: 10.1002/ppul.25431] [Reference Citation Analysis]
2 Shandro BM, Nagarajah R, Poullis A. Challenges in the management of pancreatic exocrine insufficiency. World J Gastrointest Pharmacol Ther 2018;9:39-46. [PMID: 30397535 DOI: 10.4292/wjgpt.v9.i5.39] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
3 Ng C, Major G, Smyth AR. Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis. Cochrane Database Syst Rev 2021;8:CD013488. [PMID: 34339047 DOI: 10.1002/14651858.CD013488.pub2] [Reference Citation Analysis]
4 Stallings VA, Tindall AM, Mascarenhas MR, Maqbool A, Schall JI. Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial. PLoS One 2020;15:e0232685. [PMID: 32384122 DOI: 10.1371/journal.pone.0232685] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]